

Validation data for BV6

<https://www.invivogen.com/bv6>

For research use only

Version 21G30-MM

BV6 is a potent and selective inhibitor of cIAPs (inhibitor of apoptosis proteins). BV6 induces rapid degradation of cIAP, thus allowing for TNF- α (tumor necrosis factor- α)-induced and RIPK1 (receptor-interacting serine/threonine-protein kinase 1)-dependent apoptosis or necroptosis. The ability of BV6 to inhibit RIPK1-RIPK3-MLKL necrosome-mediated necroptosis upon TNF- α (tumor necrosis factor- α) signaling and Caspase-8 inhibition was validated using InvivoGen's THP1-HMGB1-Lucia™ cellular assay (**Figure 1**).

Dose-dependent induction of necroptosis




Figure 1: BV6 contributes to TNF- α -induced cell death a dose-dependent manner.

THP1-HMGB1-Lucia™ cells were incubated with recombinant human TNF- α (100 ng/ml), Z-VAD-FMK (pan-caspase inhibitor, 25 μ M), and increasing concentrations of BV6 (cIAP inhibitor). After overnight incubation, the level of HMGB1::Lucia released in the supernatant was assessed by measuring the light signal produced using the QUANTI-Luc™ detection reagent. Data are shown as a percentage (%) of maximal cell death induction.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3622-3480
E-mail: info@invivogen.com